Repligen Co. (NASDAQ:RGEN) Shares Purchased by Signaturefd LLC

Signaturefd LLC boosted its holdings in Repligen Co. (NASDAQ:RGEN) by 48.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 417 shares of the biotechnology company’s stock after purchasing an additional 136 shares during the quarter. Signaturefd LLC’s holdings in Repligen were worth $75,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in RGEN. Milestone Investment Advisors LLC acquired a new stake in Repligen during the third quarter worth about $61,000. Headlands Technologies LLC acquired a new stake in Repligen during the third quarter worth about $75,000. Nisa Investment Advisors LLC increased its stake in Repligen by 67.6% during the third quarter. Nisa Investment Advisors LLC now owns 533 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 215 shares during the last quarter. Annis Gardner Whiting Capital Advisors LLC acquired a new stake in Repligen during the third quarter worth about $95,000. Finally, Operose Advisors LLC acquired a new stake in Repligen during the third quarter worth about $99,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

RGEN has been the subject of several research analyst reports. Stifel Nicolaus upped their price target on Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a research note on Thursday, February 22nd. KeyCorp increased their target price on Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a research note on Thursday, February 15th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $196.70.

Repligen Price Performance

RGEN stock opened at $158.36 on Thursday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.75 and a current ratio of 7.02. Repligen Co. has a 1 year low of $110.45 and a 1 year high of $211.13. The firm has a market cap of $8.84 billion, a P/E ratio of 219.95, a price-to-earnings-growth ratio of 5.44 and a beta of 1.02. The stock has a 50-day simple moving average of $181.94 and a 200-day simple moving average of $173.85.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 EPS for the quarter, meeting analysts’ consensus estimates of $0.33. The firm had revenue of $155.74 million during the quarter, compared to the consensus estimate of $155.38 million. Repligen had a return on equity of 5.00% and a net margin of 6.51%. Repligen’s revenue for the quarter was down 16.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.68 earnings per share. On average, equities analysts predict that Repligen Co. will post 1.46 earnings per share for the current fiscal year.

Insider Activity at Repligen

In related news, COO James Bylund sold 4,373 shares of the stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $198.08, for a total value of $866,203.84. Following the completion of the transaction, the chief operating officer now owns 14,135 shares of the company’s stock, valued at $2,799,860.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, COO James Bylund sold 4,373 shares of the stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $198.08, for a total value of $866,203.84. Following the completion of the transaction, the chief operating officer now owns 14,135 shares of the company’s stock, valued at $2,799,860.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Anthony Hunt sold 16,707 shares of the stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $197.44, for a total value of $3,298,630.08. Following the completion of the transaction, the chief executive officer now directly owns 185,249 shares of the company’s stock, valued at approximately $36,575,562.56. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 25,597 shares of company stock valued at $5,039,532. Insiders own 1.20% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.